GE BioPharma sale to Danaher is complete

By The Science Advisory Board staff writers

April 1, 2020 -- The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

As part of Danaher, the business will be called Cytiva and will operate as a standalone company within Danaher's Life Sciences segment.

The deal, which was originally announced in February 2019, was completed with a cash consideration of around $20 billion to GE as well as Danaher's assumption of certain pension liabilities.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.